Literature DB >> 2464364

Decrease of prostaglandin I2 binding sites in thyroid cancer.

I Virgolini1, M Hermann, H Sinzinger.   

Abstract

The properties of specific prostaglandin I2 (prostacyclin, PGI2) binding sites in normal thyroid tissue have been characterised. Tissue samples obtained intraoperatively from patients with 'cold' solitary thyroid nodules (as preoperatively selected by thyroid gland scintigraphy, thyroid gland ultrasonography and Papanicolaou cytology following fine needle aspiration of the nodule area) have been used for thyroid membrane preparation. Employing [3H]iloprost, a chemically stable PGI2-analogue as a radioligand, saturation experiments for comparative binding studies have been attempted. Scatchard analysis of the binding data obtained for normal thyroid parenchyma distant to the nodule area revealed heterogeneity of the [3H]iloprost sites exhibiting a high-affinity binding capacity (Bmax) of 613.2 +/- 130.4 fmol mg-1 membrane protein and a low-affinity binding capacity of 5.1 +/- 1.6 pmol mg-1 membrane protein. The equilibrium dissociation constant (Kd) amounted to 18.9 +/- 8.9 nM and to 131.5 +/- 39.2 nM, respectively. Scatchard analysis of the binding data obtained for benign thyroid adenoma indicated significant lower binding capacities exhibiting a Bmax of 325.8 +/- 110.0 fmol mg-1 membrane protein (Kd: 31.0 +/- 7.5 nM) for the high-affinity sites and of 3.9 +/- 2.5 pmol mg-1 membrane protein (Kd: 364.9 +/- 183.6) for the low affinity sites. In cancer tissue a selective loss of the low affinity sites and a significant diminution of the high-affinity sites was observed: in well differentiated cancer the high-affinity sites showed a Bmax of 299.7 +/- 46.0 fmol mg-1 membrane protein (Kd: 38.9 +/- 7.3 nM), in anaplastic cancer, less differentiated papillar and follicular cancers of 180.6 +/- 25.1 fmol mg-1 membrane protein (Kd: 54.6 +/- 16.7 nM). Well differentiated papillar and follicular cancers did not differ from each other.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464364      PMCID: PMC2246842          DOI: 10.1038/bjc.1988.264

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Binding of 3H-iloprost to rat gastric mucosa: a pitfall in performing radioligand binding assays.

Authors:  M Beinborn; W Kromer; U Staar; K F Sewing
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1985-09

2.  Demonstration of a thyrotropin-responsive prostaglandin E2-9-ketoreductase in bovine thyroid.

Authors:  Y Friedman; S Levasseur; G Burke
Journal:  Biochim Biophys Acta       Date:  1976-06-22

3.  In vitro effects of arachidonic acid and of inhibitors of its metabolism on the dog thyroid gland.

Authors:  J M Boeynaems; J Van Sande; C Decoster; J E Dumont
Journal:  Prostaglandins       Date:  1980-04

4.  Prostacyclin stimulation of adenylate cyclase activity in human thyroid membranes.

Authors:  K Kasai; M Hiraiwa; Y Suzuki; N Banba; T Emoto; T Nakamura; S I Shimoda
Journal:  Horm Metab Res       Date:  1986-09       Impact factor: 2.936

5.  Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse.

Authors:  V Hial; Z Horakova; F E Shaff; M A Beaven
Journal:  Eur J Pharmacol       Date:  1976-06       Impact factor: 4.432

6.  Prostaglandins stimulate thyroid function in pregnant women.

Authors:  L Shenkman; Y Imai; K Kataoka; C S Hollander; L Wan; S C Tang; T AvRuskin
Journal:  Science       Date:  1974-04-05       Impact factor: 47.728

7.  Evidence for high affinity prostacyclin binding sites in vascular tissue: radioligand studies with a chemically stable analogue.

Authors:  W Rücker; K Schrör
Journal:  Biochem Pharmacol       Date:  1983-08-15       Impact factor: 5.858

8.  The different modes of action of thyrotropin and prostaglandin E1 on cyclic adenosine 3',5'-monophosphate synthesis in human thyroid, as studied by sequential stimulations.

Authors:  N Takasu; S Sato; T Yamada; M Makiuchi; R Furihata
Journal:  Horm Metab Res       Date:  1976-05       Impact factor: 2.936

9.  Direct evidence for a prostaglandin receptor and its application to prostaglandin measurements (rat-adipocytes-antagonists-analogues-mouse ovary assay).

Authors:  F A Kuehl; J L Humes
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

10.  Effect of prostaglandins and hormones on cyclic AMP formation in rat hepatomas and liver tissue.

Authors:  G O Brønstad; T Christoffersen; E J Johansen; I Oye
Journal:  Br J Cancer       Date:  1978-12       Impact factor: 7.640

View more
  5 in total

1.  99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.

Authors:  I Virgolini; P Angelberger; C Müller; J O'Grady; H Sinzinger
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

2.  [Prostaglandin interaction in the human liver].

Authors:  I Virgolini; K Weiss; M Hermann; C Müller; H Sinzinger
Journal:  Klin Wochenschr       Date:  1989-12-15

3.  Human hepatocellular cancers show decreased prostaglandin E1 binding capacity.

Authors:  I Virgolini; H Sinzinger; C Müller; M Hermann
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

4.  Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.

Authors:  I Virgolini; C Müller; W Klepetko; P Angelberger; H Bergmann; J O'Grady; H Sinzinger
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

5.  Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.

Authors:  S R Li; Q Yang; E Wandl; W Pirker; I Virgolini
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.